Clinical outcome and peripheral immune profile of myasthenic crisis with omicron infections: A prospective cohort study
Clin Immunol. 2023 Dec 22:109879. doi: 10.1016/j.clim.2023.109879. Online ahead of print.ABSTRACTThe impact of Omicron infections on the clinical outcome and immune responses of myasthenia gravis (MG) remained largely unknown. From a prospective multicenter MG cohort (n = 189) with 197 myasthenic crisis (MC), we finally included 41 independent MG patients to classify into two groups: the Omicron Group (n = 13) and the Control Group (n = 28). In this matched cohort study, all-cause mortality was 7.69% (1/13) in Omicron Group and 14.29% (4/28) in Control Group. A higher proportion of elevated serum IL-6 was identified in the...
Source: Clinical Immunology - December 24, 2023 Category: Allergy & Immunology Authors: Xiao Huan Jialin Chen Huahua Zhong Yafang Xu Yuan Wang Haoqin Jiang Jie Song Chong Yan Jianying Xi Zhangyu Zou Jianming Zheng Zhe Ruan Song Tan Lijun Luo Sushan Luo Chongbo Zhao Pan-Yangtze River Delta Alliance for Neuromuscular Disorders (PYDAN) Li Zeng Source Type: research
Autonomic nervous system involvement in autoimmune encephalitis and paraneoplastic neurological syndromes
Rev Neurol (Paris). 2023 Dec 22:S0035-3787(23)01150-5. doi: 10.1016/j.neurol.2023.12.001. Online ahead of print.ABSTRACTIn autoimmune neurological diseases, the autonomic nervous system can be the primary target of autoimmunity (e.g. autoimmune autonomic ganglionopathy), or, more frequently, be damaged together with other areas of the nervous system (e.g. Guillain-Barré syndrome). Patients with autoimmune encephalitis and paraneoplastic neurological syndromes (PNS) often develop dysautonomia; however, the frequency and spectrum of autonomic signs and symptoms remain ill defined except for those scenarios in which dysauton...
Source: Revue Neurologique - December 23, 2023 Category: Neurology Authors: M Villagr án-García A Farina L Campetella J Arzalluz-Luque J Honnorat Source Type: research
Potentially inappropriate drug use in myasthenia gravis: a real-world population-based cohort study in Italy
ConclusionAmong incident users of pyridostigmine, more than 15% of patients have at least one of the contraindications considered, and among patients diagnosed with MG, in the first year of follow-up >60% of subjects were treated with potentially contraindicated drugs. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - December 21, 2023 Category: Neurology Source Type: research
Evidence for genetic causal relationships between gut microbiome, metabolites, and myasthenia gravis: a bidirectional Mendelian randomization study
ConclusionOur MR findings support the causal effects of specific gut microbiome taxa and derived metabolites on AChR antibody-positive MG, and vice versa, yielding novel insights into prevention and therapy targets of MG. Future studies may be warranted for validation and pursuing the precise mechanisms. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - December 21, 2023 Category: Allergy & Immunology Source Type: research
Eliciting Exploratory Patient Preference Data: A Case Study in a Rare Disease
ConclusionsPatient preference information can be collected using a variety of approaches, both qualitative and quantitative, tailored to fit the research needs of a study. The novel mixed-methods approach employed in this study efficiently captured patient preference data that were informative for exploratory research, internal decision making, and future research. (Source: Pharmaceutical Medicine)
Source: Pharmaceutical Medicine - December 21, 2023 Category: Drugs & Pharmacology Source Type: research
Rs1800629 polymorphism in TNF-alpha is associated with the susceptibility and initial short-term glucocorticoids efficacy in myasthenia gravis patients
In this study, we enrolled 409 adult MG patients and 487 healthy individuals to investigate the association between TNF-α polymorphism and MG. We found the rs1800629 A a llele frequency was significantly higher in the MG group than in the control group. Subgroup analysis revealed that the A allele frequencies were significantly higher in the early-onset subgroup, non-thymoma subgroup, ocular-onset subgroup, and mild severity subgroup than in the control group. (Source: Journal of Neuroimmunology)
Source: Journal of Neuroimmunology - December 20, 2023 Category: Allergy & Immunology Authors: Hong-Yan Li, Meng Xia, Min Song, Yanchen Xie, Qi Wang, Yao-Xian Yue, Hai-Feng Li Source Type: research
Effectiveness of early glucocorticoids in myasthenia gravis: a retrospective cohort study
ConclusionEarly intervention with GC led to better long-term outcomes and reduced the necessary maintenance dose of oral GC for patients with MG. EOMG and OMG were positive predictors of MM status or better with mono-GC. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - December 19, 2023 Category: Neurology Source Type: research
